CN Patent

CN106883212A — 一种xli晶型阿昔替尼的制备方法

Assigned to HEFEI TOPWAY BIOTECHNOLOGY CO Ltd · Expires 2017-06-23 · 9y expired

What this patent protects

本发明公开了一种XLI晶型阿昔替尼的制备方法，其特征在于，包括如下步骤：S1、在避光环境中，将阿昔替尼、质子性溶剂混匀，重结晶，干燥得到中间体；S2、在避光环境中，取S1得到的中间体在无水溶剂中进行加晶种重结晶得到XLI晶型阿昔替尼。本发明操作简便，重复性高，成本低，收率高，适合工业化生产。

USPTO Abstract

本发明公开了一种XLI晶型阿昔替尼的制备方法，其特征在于，包括如下步骤：S1、在避光环境中，将阿昔替尼、质子性溶剂混匀，重结晶，干燥得到中间体；S2、在避光环境中，取S1得到的中间体在无水溶剂中进行加晶种重结晶得到XLI晶型阿昔替尼。本发明操作简便，重复性高，成本低，收率高，适合工业化生产。

Drugs covered by this patent

Patent Metadata

Patent number
CN106883212A
Jurisdiction
CN
Classification
—
Expires
2017-06-23
Drug substance claim
No
Drug product claim
No
Assignee
HEFEI TOPWAY BIOTECHNOLOGY CO Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.